Status:
Concluded with an LOI
Manufacturer:
AVIR Pharma Inc.
Indication:
Ulcerative Colitis
Last updated December 17, 2023
Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
Status:
Concluded with an LOI
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Indication:
Cystic fibrosis, F508del CFTR mutation, 2 years and older
Last updated December 12, 2023
Breyanzi (lisocabtagene maraleucel)
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma
Last updated December 12, 2023
Status:
Negotiations were not pursued
Manufacturer:
Sandoz Canada Inc.
Indication:
Intermediate- or high-risk T-cell acute lymphoblastic leukemia (T-ALL), addition to front-line multi-agent therapy of pediatric, adolescent, and young adult (AYA) patients (aged 1 year to 30 years at diagnosis)
Last updated December 4, 2023
Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
Adjunct to standard of care therapy for chronic kidney disease and type 2 diabetes
Last updated November 16, 2023
Status:
Concluded with an LOI
Manufacturer:
Celgene Inc.
Indication:
Ulcerative Colitis
Last updated November 10, 2023
Status:
Concluded without agreement
Manufacturer:
Janssen Inc.
Indication:
Non-small cell lung cancer (NSCLC), Locally advanced or metastatic, in adult patients with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy
Last updated November 3, 2023
Status:
Concluded with an LOI
Manufacturer:
BeiGene, Ltd.
Indication:
Chronic lymphocytic leukemia (CLL) in adult patients
Last updated November 2, 2023
Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
Metastatic castration sensitive prostate cancer (mCSPC) in combination with docetaxel
Last updated November 1, 2023
Tecartus (brexucabtagene autoleucel)
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
Acute lymphoblastic leukemia (ALL), B-cell precursor, in adult patients, relapsed or refractory
Last updated October 27, 2023